Stay updated on AFM13-NK vs AFM13 in Lymphoma Clinical Trial

Sign up to get notified when there's something new on the AFM13-NK vs AFM13 in Lymphoma Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the AFM13-NK vs AFM13 in Lymphoma Clinical Trial page

  1. Check
    yesterday
    No Change Detected
  2. Check
    2 days ago
    No Change Detected
  3. Check
    3 days ago
    Change Detected
    Summary
    The value 7 has recently changed to 8 on the webpage, indicating a potential update in the dose or measurement of a medical treatment involving modified umbilical cord blood immune cells and the antibody AFM13 for patients with CD30 positive Hodgkin or Non-Hodgkin Lymphomas.
    Difference
    0.1%
    Check dated 2024-06-06T14:23:32.000Z thumbnail image
  4. Check
    6 days ago
    No Change Detected
  5. Check
    7 days ago
    No Change Detected
  6. Check
    17 days ago
    Change Detected
    Summary
    The 'Participation Criteria' section has been updated to include detailed eligibility criteria for patients with specific types of lymphoma, including health conditions and prior treatments, replacing the previous placeholder text that indicated no information was provided.
    Difference
    31%
    Check dated 2024-05-22T20:22:20.000Z thumbnail image
  7. Check
    39 days ago
    Change Detected
    Difference
    1.0%
    Check dated 2024-04-30T22:54:19.000Z thumbnail image

Stay in the know with updates to AFM13-NK vs AFM13 in Lymphoma Clinical Trial

Enter your email address, and we'll notify you when there's something new on the AFM13-NK vs AFM13 in Lymphoma Clinical Trial page.